	US 12,257,296 B2
	Chimeric RSV, immunogenic compositions, and methods of use
Martin L. Moore, Decatur, GA (US); and Christina Rostad, Atlanta, GA (US)
Assigned to Emory University, Atlanta, GA (US)
Filed by EMORY UNIVERSITY, Atlanta, GA (US)
Filed on Jan. 14, 2022, as Appl. No. 17/575,829.
Application 17/575,829 is a continuation of application No. 15/772,275, granted, now 11,235,050, previously published as PCT/US2016/058976, filed on Oct. 27, 2016.
Claims priority of provisional application 62/334,547, filed on May 11, 2016.
Claims priority of provisional application 62/247,962, filed on Oct. 29, 2015.
Prior Publication US 2023/0293660 A1, Sep. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01); A61P 11/00 (2006.01)

CPC A61K 39/12 (2013.01) [C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/5254 (2013.01); A61P 11/00 (2018.01); C12N 2760/18521 (2013.01); C12N 2760/18534 (2013.01); C12N 2760/18562 (2013.01)]

16 Claims

1. A respiratory syncytial virus (RSV) F protein comprising K at position 357 and Y at position 371, each relative to amino acid sequence as set forth in SEQ ID NO: 4, provided that the RSV F protein has less than 98% sequence identity to SEQ ID NO: 4; and wherein the RSV F protein has more than 90% sequence identity to SEQ ID NO: 1.